Cigna Extends Coverage of Brainsway’s Brain Stimulator to Treat OCD

Obsessive-compulsive disorder (OCD) It was Rank by World Health Organization As one of the 10 most debilitating medical conditions in terms of income loss and reduced quality of life. The condition is complex and presents differently in each patient, and many of them are drug-resistant. These challenges make treating OCD difficult. Many patients with this condition do not respond well to traditional treatment options, such as cognitive behavioral therapy and medication.

Brainswayan Israeli company that provides non-invasive neurostimulation therapies for mental health disorders, and is working to solve this problem by Transcranial magnetic stimulation (TMS) device. Thursday, Cigna announced that he is review Its Medical TMS coverage policy to expand Brainsway’s Deep TMS coverage to patients 18 years of age or older who have been diagnosed with OCD.

With its policy change, Cigna now joins several other major insurers that cover the device, including two centsAnd the high markAnd the Blue Cross Blue ShieldAnd the trekker And the Palmetto GBA. CEO Christopher von Jakow said more than 86 million adults now have access to BrainsWay’s deep TMS treatment for obsessive-compulsive disorder.

TMS is a non-invasive treatment that activates brain structures through directed electromagnetic fields that generate excitation of neurons. Brainsway specializes in deep TMS treatment, an evolution of traditional TMS. The Deep TMS system uses flexible H coils embedded in a helmet that is easy to use for the patient and operator. These drugs noninvasively activate targeted brain structures that can treat a range of mental health conditions.

The Brainway’s H-Coil design allows for deeper and broader stimulation than traditional TMS coils, according to von Jako. This results in greater activation of neurons and reduced potential for targeting errors.

There are companies that offer traditional TMS solutions – such as Neurology And the Magventurewhich has also approved devices to treat obsessive-compulsive disorder in the United States, but von Jako stresses that Brainsway is the only company to offer deep TMS.

Patients using Brainway’s Deep TMS for OCD use it daily for anywhere from 3 to 20 minutes. They use it for at least four weeks, with the option to later incorporate it into their daily schedule, according to von Jaco. Since its introduction in 2019, the Brainsway device’s response rate in real clinical practice settings has been close to 60%, with an average durability of about two years.

Under Cigna’s updated coverage policy, an initial deep TMS treatment session regimen will be classified as medically necessary if a patient meets the following two criteria: two or more failed drug trials and one evidence-based psychotherapy experience without significant improvement in symptoms. This treatment regimen includes 30-36 sessions.

The policy also states that patients who experience a 30% or more improvement in their score in Yale Brown Obsessive Compulsive Scale The most common obsessive-compulsive disorder rating scale – kept for at least 2 months are candidates for an additional regimen of 30 to 36 additional sessions.

Cigna is one of the largest health plans in the United States — it provides commercial health coverage to nearly 17 million members in 13 states and has Medicare Advantage plans in 16 states. Cigna also participates in the online health insurance marketplace exchange. Von Jako said having a positive coverage policy is a big step for Brainsway.

“If I had been talking to you about a year ago, I would have told you we had zero coverage for deep TMS treatment for OCD patients,” he said. “With Cigna’s Positive Coverage Policy, we have increased coverage to more than 85 million people in the United States, we still have a lot of work to do, and we plan to continue working our way toward more positive coverage to increase patients’ access to this life-providing treatment. “.

Photo: SIphotography, Getty Images

Leave a Comment